Status
Conditions
Treatments
About
Shoulder arthroscopy can cause moderate to severe pain after surgery. An interscalene block is commonly used to reduce this pain, but it may temporarily weaken movement of the diaphragm on the treated side.
This study will compare an interscalene block with a combination of suprascapular nerve block and PECS I block in adults undergoing elective shoulder arthroscopy. The researchers want to determine whether the combined blocks provide pain relief that is not meaningfully worse than the interscalene block while causing less impairment of diaphragm movement.
A total of 80 participants will be randomly assigned to one of two groups. All participants will receive general anesthesia. At the end of surgery, while participants are still under anesthesia, one group will receive the combined suprascapular nerve and PECS I blocks, and the other group will receive an interscalene block. Both groups will use the same intravenous patient-controlled pain pump containing tramadol after surgery.
The main outcome will be the total amount of tramadol used during the first 24 hours after surgery. The study will also assess pain scores, diaphragm movement measured by ultrasound, quality of recovery, time until additional pain medicine is first needed, nausea and vomiting, anti-nausea medicine use, and block-related side effects during the first 24 hours.
Full description
Interscalene brachial plexus block provides effective analgesia after shoulder surgery but is associated with ipsilateral phrenic nerve blockade and hemidiaphragmatic dysfunction. These effects may limit its use, particularly in patients with reduced respiratory reserve. The combination of suprascapular nerve block and PECS I block may provide broader coverage of the sensory innervation of the shoulder while reducing the risk of phrenic nerve involvement.
This prospective, single-center, randomized, single-blind, parallel-group, active-controlled non-inferiority trial will include 80 adults aged 18 to 75 years with American Society of Anesthesiologists physical status I to III who are scheduled for elective arthroscopic shoulder surgery. Participants will be randomly allocated in a 1:1 ratio to the combined-block group or the interscalene-block group.
All participants will receive standardized general anesthesia. At the end of surgery and before emergence from anesthesia, participants in the combined-block group will receive an ultrasound-guided suprascapular nerve block with 15 mL of 0.25% bupivacaine and an ultrasound-guided PECS I block with 10 mL of 0.25% bupivacaine. Participants in the interscalene-block group will receive an ultrasound-guided interscalene brachial plexus block with 15 mL of 0.5% bupivacaine.
Postoperative analgesia will be standardized in both groups using intravenous patient-controlled analgesia with tramadol. Pain intensity will be assessed using the 0-to-10 Numeric Rating Scale at 1, 6, 12, and 24 hours after surgery and during the first supervised postoperative exercise. Rescue analgesia with 50 mg of intravenous tramadol will be administered when the Numeric Rating Scale score is 4 or higher.
The primary objective is to determine whether the combined suprascapular nerve and PECS I blocks are non-inferior to the interscalene block with respect to cumulative tramadol consumption during the first 24 postoperative hours. The prespecified non-inferiority margin is 25% of the reference mean tramadol consumption in the interscalene-block group.
Hemidiaphragmatic excursion on the operated side will be measured using M-mode ultrasonography before surgery and 30 minutes after block administration in the post-anesthesia care unit. Additional outcomes will include postoperative pain scores, Quality of Recovery-15 score at 24 hours, time to first rescue analgesic administration, postoperative nausea and vomiting, antiemetic consumption, and block-related adverse events, including Horner syndrome, hoarseness, paresthesia, hematoma, and local anesthetic systemic toxicity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
80 participants in 2 patient groups
Loading...
Central trial contact
cansu ofluoglu, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal